#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Kevin Healy Email
SVP, Regulatory Affairs, Pharmacovigilance, and Quality . Enzyvant
How to contact Kevin Healy
Join and see Kevin's contact info for free!Current Roles
Employees:
27Revenue:
$4.2MAbout
About Enzyvant Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant's lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration expedited designation as a Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma), a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the US, China and the EU as well as talent, knowledge and resources across a wide spectrum of technologies and therapeutic areas.Enzyvant Address
55 Cambridge ParkwayCambridge, MA
United States